Business Description
Repligen Corp
NAICS : 339112
SIC : 3841
ISIN : US7599161095
Description
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.43 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.22 | |||||
| Debt-to-EBITDA | 1.91 | |||||
| Interest Coverage | 118.77 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 10.22 | |||||
| Beneish M-Score | -2.5 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 36.4 | |||||
| 3-Year EBITDA Growth Rate | 60.4 | |||||
| 3-Year EPS without NRI Growth Rate | 94.5 | |||||
| 3-Year FCF Growth Rate | -9 | |||||
| 3-Year Book Growth Rate | 19.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 6.15 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.86 | |||||
| 9-Day RSI | 44.76 | |||||
| 14-Day RSI | 45.69 | |||||
| 6-1 Month Momentum % | -1.36 | |||||
| 12-1 Month Momentum % | -8.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.67 | |||||
| Quick Ratio | 2.03 | |||||
| Cash Ratio | 1.62 | |||||
| Days Inventory | 260.11 | |||||
| Days Sales Outstanding | 60.93 | |||||
| Days Payable | 30.93 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.2 | |||||
| Shareholder Yield % | -0.62 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 53.61 | |||||
| Operating Margin % | 18.61 | |||||
| Net Margin % | 18.93 | |||||
| ROE % | 7.29 | |||||
| ROA % | 5.51 | |||||
| ROIC % | 6.18 | |||||
| ROC (Joel Greenblatt) % | 27.9 | |||||
| ROCE % | 7.75 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 66.6 | |||||
| Forward PE Ratio | 72.52 | |||||
| PE Ratio without NRI | 66.6 | |||||
| Shiller PE Ratio | 141.37 | |||||
| Price-to-Owner-Earnings | 99.77 | |||||
| PEG Ratio | 1.3 | |||||
| PS Ratio | 12.65 | |||||
| PB Ratio | 4.56 | |||||
| Price-to-Tangible-Book | 12 | |||||
| Price-to-Free-Cash-Flow | 179.7 | |||||
| Price-to-Operating-Cash-Flow | 61.91 | |||||
| EV-to-EBIT | 53.68 | |||||
| EV-to-Forward-EBIT | 57.24 | |||||
| EV-to-EBITDA | 39.53 | |||||
| EV-to-Forward-EBITDA | 45.26 | |||||
| EV-to-Revenue | 11.98 | |||||
| EV-to-Forward-Revenue | 11.14 | |||||
| EV-to-FCF | 169.43 | |||||
| Price-to-Projected-FCF | 4.32 | |||||
| Price-to-DCF (Earnings Based) | 2.12 | |||||
| Price-to-DCF (FCF Based) | 12.63 | |||||
| Price-to-Median-PS-Value | 0.96 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.65 | |||||
| Price-to-Graham-Number | 5.93 | |||||
| Price-to-Net-Current-Asset-Value | 21.28 | |||||
| Price-to-Net-Cash | 348.76 | |||||
| Earnings Yield (Greenblatt) % | 1.86 | |||||
| Forward Rate of Return (Yacktman) % | 20.47 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RGEN
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Repligen Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 729.332 | ||
| EPS (TTM) ($) | 2.42 | ||
| Beta | 0.98 | ||
| Volatility % | 37.43 | ||
| 14-Day RSI | 45.69 | ||
| 14-Day ATR ($) | 5.242223 | ||
| 20-Day SMA ($) | 164.887 | ||
| 12-1 Month Momentum % | -8.95 | ||
| 52-Week Range ($) | 134.64 - 225.62 | ||
| Shares Outstanding (Mil) | 55.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Repligen Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Repligen Corp Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Repligen Corp Frequently Asked Questions
What is Repligen Corp(RGEN)'s stock price today?
The current price of RGEN is $161.16. The 52 week high of RGEN is $225.62 and 52 week low is $134.64.
When is next earnings date of Repligen Corp(RGEN)?
The next earnings date of Repligen Corp(RGEN) is 2023-11-01 Est..
Does Repligen Corp(RGEN) pay dividends? If so, how much?
Repligen Corp(RGEN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers